Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP2 on Glucose Metabolism and Food Intake in Obesity
NCT05603598Unknown
- Sponsor
- Gentofte Hospital
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of liver-expressed antimicrobial peptide 2 in obesity (2 arms), sponsored by Gentofte Hospital. Primary endpoints: Food intake and Food intake per kilogram body weight. Status: unknown.
02
Drugs
liver-expressed antimicrobial peptide 2
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05603598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603598.